|
| Press Releases |
|
 |
|
| Thursday, May 2, 2024 |
|
|
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore |
| Mainboard listed Q&M Dental Group (Singapore) Limited ("Q&M" or "the Company" and together with its subsidiaries, the "Group") is proud to announce its integration of Align Technology's ("Align") iTero Lumina(TM) Intraoral Scanner in Singapore. more info >> |
|
| Tuesday, April 23, 2024 |
|
|
EM2AI Revolutionising the Dental Industry: New AI Products Promise Transparent Treatment Plans for Patients |
| EM2AI Pte. Ltd., ("EM2AI" or the "Company") an Artificial Intelligence (AI) dental healthcare company based in Singapore today announced a groundbreaking development poised to reshape the landscape of dental care, with the launch of its pioneering dental AI product. more info >> |
|
| Friday, March 3, 2023 |
|
|
CATALIST-listed AOXIN Q&M reports lower revenue of RMB 140m for full year ended 31 December 2022 |
| Catalist listed Aoxin Q&M Dental Limited, announced on 1 March 2023, a 12.8% lower revenue of RMB139.7 million for full year ended 31 December 2022 (FY2022). The Group reported a net loss after tax excluding impairment loss on investment in our associate of RMB7.3 million for FY2022, primarily due to the number of shutdowns from China's zero-Covid policy that was in place all the way up until 8 January 2023. more info >> |
|
| Wednesday, February 23, 2022 |
|
|
CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021 |
| Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021"). more info >> |
|
| Monday, October 4, 2021 |
|
|
Aoxin Q & M acquires 49% stake in Acumen Diagnostics for S$29.4m |
| Aoxin Q & M Dental Group Ltd (SGX: 1D4.SI) ("Aoxin Q & M") and Q & M Dental Group (Singapore) Limited (SGX: QC7.SI) ("Q & M"), announced today that Aoxin Q & M will acquire 49% of Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") for a consideration of S$29.4 million. Acumen Diagnostics has a preliminary valuation of S$60 million. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
 |
Mint Signed MoU with Robotics Leader Rice Robotics to Pioneer Physical AI Solutions Across Asia
Feb 10, 2026 16:29 HKT/SGT
|
|
|
KS Energy and Hitachi Collaborate on Extra-High Voltage Battery Energy Storage System
Feb 10, 2026 14:15 JST
|
|
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 10, 2026 13:34 JST
|
|
|
Spritzer EcoPark Gallops into the Year of the Horse with a Tradition-Inspired Chinese New Year Celebration
Feb 10, 2026 11:49 HKT/SGT
|
|
|
NEC Exhibits at MWC Barcelona 2026, the World's Largest Mobile-Related Exhibition
Feb 9, 2026 21:18 JST
|
|
|
CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence
Feb 9, 2026 13:28 HKT/SGT
|
|
|
JCB Announces Collaboration with Resorts World Sentosa in Singapore
Feb 9, 2026 14:00 JST
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Feb 9, 2026 11:00 JST
|
|
|
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
Feb 8, 2026 23:30 HKT/SGT
|
|
|
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.
Feb 7, 2026 05:45 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025
Feb 6, 2026 13:13 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|